Outcomes after heart retransplantation: A 50-year single-center experience.


Journal

The Journal of thoracic and cardiovascular surgery
ISSN: 1097-685X
Titre abrégé: J Thorac Cardiovasc Surg
Pays: United States
ID NLM: 0376343

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 15 01 2020
revised: 10 06 2020
accepted: 27 06 2020
pubmed: 17 8 2020
medline: 1 2 2022
entrez: 17 8 2020
Statut: ppublish

Résumé

To evaluate outcomes after heart retransplantation. From January 6, 1968, to June 2019, 123 patients (112 adult and 11 pediatric patients) underwent heart retransplantation, and 2092 received primary transplantation at our institution. Propensity-score matching was used to account for baseline differences between the retransplantation and the primary transplantation-only groups. Kaplan-Meier survival analyses were performed. The primary end point was all-cause mortality, and secondary end points were postoperative complications. Retransplantation recipient age was 39.6 ± 16.4 years, and donor age was 26.4 ± 11.2 years. Ninety-two recipients (74.8%) were male. Compared with recipients who only underwent primary heart transplantation, retransplantation recipients were more likely to have hypertension (44/73.3% vs 774/53.3%, P = .0022), hyperlipidemia (40/66.7% vs 447/30.7%, P < .0001), and require dialysis (7/11.7% vs 42/2.9%, P = .0025). The indications for heart retransplantation were cardiac allograft vasculopathy (32/80%), primary graft dysfunction (6/15%), and refractory acute rejection (2/5%). After matching, postoperative outcomes such as hospital length of stay, severe primary graft dysfunction requiring intra-aortic balloon pump or extracorporeal membrane oxygenation, cerebral vascular accident, respiratory failure, renal failure requiring dialysis, and infection were similar between the 2 groups. Matched median survival after retransplantation was 4.6 years compared with 6.5 years after primary heart transplantation (log-rank P = .36, stratified log-rank P = .0063). In this single-center cohort, the unadjusted long-term survival after heart retransplantation was inferior to that after primary heart transplantation, and short-term survival difference persisted after propensity-score matching. Heart retransplantation should be considered for select patients for optimal donor organ usage.

Identifiants

pubmed: 32798029
pii: S0022-5223(20)32145-0
doi: 10.1016/j.jtcvs.2020.06.121
pii:
doi:

Types de publication

Comparative Study Journal Article Observational Study Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

712-720.e6

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Yuanjia Zhu (Y)

Department of Cardiothoracic Surgery, Stanford University, Stanford, Calif.

Yasuhiro Shudo (Y)

Department of Cardiothoracic Surgery, Stanford University, Stanford, Calif.

Bharathi Lingala (B)

Department of Cardiothoracic Surgery, Stanford University, Stanford, Calif.

Michael Baiocchi (M)

Department of Epidemiology and Population Health, Stanford University, Stanford, Calif.

Philip E Oyer (PE)

Department of Cardiothoracic Surgery, Stanford University, Stanford, Calif.

Y Joseph Woo (YJ)

Department of Cardiothoracic Surgery, Stanford University, Stanford, Calif. Electronic address: joswoo@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH